Used for two thousand years in Chinese and Japanese practice for headache with vomiting and cold-type stomach pain. The biology is real and the clinical case is unmade — animal effects have not been demonstrated in people. Against that thin benefit picture sits a liver-injury signal and a potent liver-enzyme effect that can quietly strip other medicines of their effect. (Full Review)

Protocol

Standard traditional protocol

3–9 g/day dried fruit

Decoction of dried unripe fruit, divided into two or three servings taken morning, midday and evening.

Chinese Pharmacopoeia protocol

2–5 g/day

More conservative, reflecting the fruit's formal slightly-toxic classification; the safer starting point.

Best time of day

With meals, morning and evening

Late-evening dosing is avoided because the enzyme-induction effect on caffeine and melatonin clearance can disturb sleep.

Time to effect

4–8 weeks

Digestive and headache effects in traditional use are described within days; the traditional headache formula needed 8 weeks to separate from placebo.

Sensory desensitization

Days

Warming and irritant sensations fade with repeated exposure; this is expected and is not evidence that the underlying pharmacology has stopped.

Cycling

4–8 weeks on

With a 2–4 week washout; the rationale is limiting cumulative liver exposure rather than preserving efficacy.

Benefits

Low: Preclinical antitumour activity; headache and migraine relief in traditional formulas; gastrointestinal symptom relief; blood pressure lowering; blood lipid and atherosclerotic plaque reduction; fat loss and heat production

Speculative: Cognitive protection; insulin sensitization

Contraindications

Pregnancy at any stage, and breastfeeding

Any chronic liver disease (Child-Pugh Class A cirrhosis or worse, hepatitis B or C, fatty liver with ALT above the reference limit)

Chronic kidney disease with eGFR below 60 mL/min/1.73 m²

Narrow-margin CYP1A2-cleared drugs (theophylline, clozapine)

Inherited or drug-induced bleeding disorders, and the 14 days before planned surgery

Active reflux oesophagitis, peptic ulcer, or asthma with sensory-irritant triggers

Children and adolescents under 18

Key Interactions

Other CYP1A2 substrates (olanzapine, tizanidine, duloxetine, melatonin, caffeine)

CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John's wort, dexamethasone)

Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin)

Antihypertensives (amlodipine, lisinopril, losartan) and nitrates

Hepatotoxic drugs (paracetamol, methotrexate, isoniazid, high-dose statins)

Liquorice-containing herbal formulas

Additive supplements (capsaicin, ginger, garlic, fish oil, ginkgo, nattokinase, berberine)

Over-the-counter medicines (caffeine tablets, pseudoephedrine, NSAIDs, antacids)

Other interventions (surgery, alcohol, thermal stress)

Risk & Side Effects

Medium: Dose-dependent liver injury; loss of medication efficacy from enzyme induction

Low: Kidney injury; cardiotoxicity; increased bleeding tendency; airway narrowing and sensory irritation; gastrointestinal irritation

Speculative: Uterine stimulation in pregnancy; excess nerve signalling at high doses

Monitoring

Marker	Target	Why
ALT	< 25 U/L (men), < 20 U/L (women)	Earliest and most sensitive signal of liver-cell injury
AST	< 25 U/L	Confirms liver injury and flags muscle sources
ALP and total bilirubin	ALP 40–90 U/L; bilirubin 0.3–1.0 mg/dL	Detects the bile-flow pattern of drug-induced liver injury
GGT	< 20 U/L (men), < 15 U/L (women)	Sensitive marker of liver stress and enzyme induction
eGFR and creatinine	eGFR > 90 mL/min/1.73 m²; creatinine mid-reference	Tracks the kidney-injury mechanism seen in mice
Blood pressure (seated and standing)	< 120/80 mmHg seated, drop < 10 mmHg on standing	Captures the vessel-relaxing peptide effect and dizziness risk
Complete blood count with platelets	Platelets 200–300 ×10⁹/L; haemoglobin mid-reference	Baseline for the antiplatelet and bleeding signal
Relevant drug level (e.g. theophylline)	No established target — track the individual's own pre-evodia level and treat any fall below it as significant	Detects silent loss of medication efficacy from enzyme induction

Cadence: Baseline, then 4 weeks, 12 weeks, then every 6 months while use continues, with an extra liver panel two weeks after any dose increase and a repeat drug level two weeks after stopping.

Qualitative Assessment

Upper-abdominal burning, nausea or mouth dryness — the commonest early dose-limiting signals
Unusual fatigue, dark urine, pale stool or itching — the classic early warning signs of drug-induced liver injury
Easy bruising, prolonged bleeding from small cuts, or nosebleeds
Sleep-onset latency and subjective sleep quality, given the enzyme-induction effect on melatonin clearance
Dizziness or light-headedness on standing, particularly in the first two weeks
Headache frequency and pain intensity, where headache is the reason for use

Evodia rutaecarpa for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment